35
Views
6
CrossRef citations to date
0
Altmetric
Review

Pharmacotherapeutic agents in xenotransplantation

, , , &
Pages 757-769 | Published online: 24 Feb 2005

Bibliography

  • Xenotransplantation - The Transplantation Of Organs AndTissues Between Species. (Edition 2). Cooper DKC, Kemp E, Platt JL, White DJG (Eds.), Springer, Heidelberg, Germany (1997).
  • Xeno - The Promise of Transplanting Animal Organs into Humans. Cooper DKC, Lanza RP (Eds.), Oxford University Press, New York, USA (2000).
  • ••Review of all aspects of xenotransplantation for the generalreader.
  • COOPER DKC, YE Y, ROLF LL JR, ZUHDI N: The pig as a 'potential 'organ 'donor 'for 'man. In: Xenotranplantation. Cooper DKC, Kemp E, Reemtsma K, White DJG (Eds.), Springer, Heidelberg, Germany (1990:481–500.
  • YE Y, NIEKRASZ M, KOSANKE S et al 'The 'pig 'as 'a potential organ donor for man. A study of potentially Exp. Opin. Pharmacother. (2000) 1(4) transferable disease from donor pig to recipient man. Transplantation (1994) 57:694–703.
  • SACHS DH: The pig as a potential xenograft donor. Vet. Immunol. Immunopath. (1994) 43:185–191.
  • GOOD AH, COOPER DKC, MALCOLM AJ et al.: Identifica-tion of carbohydrate structures that bind human anti-porcine antibodies: implications for discordant xenog,rafting in humans. Transplant. Proc. (1992) 24:559–562.
  • •The first identification of the importance of anti-Gal antibodies in xenotransplantation.
  • ORIOL R, YE Y, KOREN E, COOPER DKC: Carbohydrate antigens of pig tissues reacting with human natural antibodies as potential targets for hyperacute vascular rejection in pig-to-man organ xenotransplantation. Transplantation (1993) 56:1433–1442.
  • COOPER DKC, KOREN E, ORIOL R: Oligosaccharides and discordant xenotransplantation. Immunol. Rev. (1994) 141:31–58.
  • SANDRIN MS, VAUGHAN HA, DABKOWSKI PL, MCKENZIEIFC: Anti-pig IgM antibodies in human serum react predominantly with Gal(1-3)Gal epitopes. Proc. Natl. Acad. Sci. USA (1993) 90:11391.
  • GALILI U, CLARK MR, SHOHET SB, BUEHLER J, MACHER BA: Evolutionary relationship between the natural antiaGal antibody and the Gala 1-3Gal epitope in primates. Proc. Natl. Acad. Sci. USA (1987) 84:1369–1373.
  • COOPER DKC, HUMAN PA, LEXER G et al.: Effects of cyclosporin and antibody adsorption on pig cardiac xenograft survival in the baboon. J. Heart Transplant. (1988) 7:238–246.
  • PERPER RJ, NAJARIAN JS: Experimental renal hetero-transplantation. 1. In widely divergent species. Transplantation (1966) 4:377–388.
  • ROSE AG, COOPER DKC, HUMAN PA, REICHENSPURNER H, REICHART B: Histopathology of hyperacute rejection of the heart: experimental and clinical observations in allografts and xenografts. J. Heart Lung Transplant. (1991) 10:223–234.
  • PLATT JL, FISCHEL RJ, MATAS AJ et al.: Immunopa-thology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation (1991) 52:214–220.
  • ALEXANDRE GPJ, GIANELLO P, LATINNE D et al.: Plasma-pheresis and splenectomy in experimental renal xenotransplantation. In: Xenograft 25. Hardy MA (Ed.), Elsevier, New York, USA (1989):259–266.
  • COOPER DKC, CAIRNS TDH, TAUBE DH: Extracorporeal irnmunoadsorption of anti-pig antibody in pigs using aGal oligosaccharide inimmnoaffinity columns. Xeno (1996) 4:27–29.
  • XU Y, LORF T, SABLINSKI T et al.: Removal of anti-porcine natural antibodies from human and nonhuman primate plasma in vitro and in vivo by a Gala 1-3 Gall31-4G1c-X immunoaffinity column. Transplantation (1998) 65:172–179.
  • KOZLOWSKI T, SHIMIZU A, LAMBRIGTS D et al Porcine kidney and heart transplantation in baboons undergoing a tolerance inducing regimen and antibody adsorption. Transplantation (1999) 67:18–30.
  • LEVENTHAL JR, DALMASSO AP, CROMWELL JW et al.:Prolongation of cardiac xenograft survival by depletion of complement. Transplantation (1993) 55:857–865.
  • PRUITT SK, BOLLINGER RR, COLLINS BH et al.: Effect ofcontinuous complement inhibition using soluble complement receptor Type 1 on survival of pig-to-primate cardiac xenografts. Transplantation (1997) 63:900–902.
  • KOBAYASHI T, TANIGUCHI S, NEETHLING FA et al.: Delayed xenograft rejection of pig-to-baboon cardiac transplants after cobra venom factor therapy. Transplantation (1997) 64:1255–1261.
  • COZZI E, WHITE DJG: The generation of transgenic pigsas potential organ donors for humans. Nature Med. (1995) 1:964.
  • MCCURRY KR, KOOYMAN DL, ALVARADO CG et al.: Human complement regulatory proteins protect swine to primate cardiac xenografts from human injury. Nature Med. 1995: 1:423–427.
  • SCHMOECKEL M, BHATTI FN, ZAIDI A et al.: Orthotopic heart transplantation in a transgenic pig-to-primate model. Transplantation (1998) 65:1570–1507.
  • ZAIDI A, SCHMOECKEL M, BHATTI F et al.: Life-supporting pig-to-primate renal xenotransplanta-tion using genetically modified donors. Transplanta-tion (1998) 65:1584–1590.
  • •Illustrates current results that can be obtained with the use of hDAF pig organs transplanted into non-human primates.
  • BHATTI FN, SCHMOECKEL M, ZAIDI A et al.: Three-month survival of hDAF transgenic pig hearts transplanted into primates. Transplant. Proc. (1999) 31:958.
  • LAMBRIGTS D, VAN CALSTER P, XU Y et al.: Pharma-cologic irnmunosuppressive therapy and extracorpo-real immunoadsorption in the suppression of antiaGal antibody in the baboon. Xenotransplantation (1998) 5:274–283.
  • LAMBRIGTS D, SACHS DH, COOPER DKC: Discordant organ xenotransplantation in primates. World experi-ence and current status. Tranplantation (1998) 66:547–561.
  • •Comprehensive review of therapeutic approaches and results achieved in the pig-to-non-human primate model.
  • BACH FH, WINKLER H, FERRAN C, HANCOCK WW, ROBSON SC: Delayed xenograft rejection. Immunol. Today. (1996) 17:379–384.
  • •Description of factors involved in acute vascular xenograft rejection.
  • GOODMAN DL, MILLAN MT, FERRAN C et al.: Mechanisms of delayed xenograft rejection. In: Xenotransplantation - The Transplantation Of Organs And Tissues Between Species (Second Edition), Cooper DKC, Kemp E, Platt JL, White DJG (Eds.), Springer, Heidelberg, Germany (1997):77–94.
  • UN SS, WEIDNER BC, BYRNE GW et al.: The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants./ Clin. Invest. (1998) 101: 1745-1756.
  • ALWAYN IPJ, BASKER M, BUHLER L, COOPER DKC: The problem of antipig antibodies in pig-to-primate xenografting: current and novel methods of depletion and/or suppression of production of antipig antibodies. Xenotransplantation (1999) 6:157–168.
  • BUHLER L, AWWAD M, BASKER M et al.: High-dose porcine hematopoietic cell transplantation combined with CD4OL blockade in baboons prevents an induced antipig humoral response. Transplantation (In Press).
  • •The first report demonstrating that co-stimulatory blockade with an anti-CD154 mAb prevents the induced humoral response in a large animal xenograft model.
  • IERINO FL, KOZLOWSKI T, SIEGEL JB etai.: Disseminated intravascular coagulation in association with the delayed rejection of pig-to-baboon renal xenografts. Transplantation (1998) 66:1439–1450.
  • BUHLER L, BASKER M, ALWAYN IPJ et al.: Coagulation and thrombotic disorders associated with pig organ and hematopoietic cell transplantation in nonhuman primates. Transplantation (In Press).
  • •Describes and discusses the thrombotic microangiopathy and DIG that can be associated with xenotransplantation.
  • KOPP CW, SIEGEL JB, HANCOCK WW et al.: Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors. Transplantation (1997) 63:749–758
  • SAADI S, HOLZKNECHT RA, PATTE CP et al.: Comple-ment regulation of tissue factor activity in endothe-lium./ Exp. Med. (1995) 182: 1807-1814
  • ROBINSON LA, TU L, STEEBER DA et al.: The role of adhesion molecules in human leukocyte attachment to porcine vascular endothelium: implications for xenotransplantation. J. Immunol. (1998) 161:6931–6938
  • KOPP CW, ROBSON SC, SIEGEL JB et al.: Regulation of monocyte tissue factor activity by allogeneic and xenogeneic endothelial cells. Thromb. Haemost. (1996) 79:529–538
  • YAMADA K, SACHS DH, DERSIMONIAN H: Human antiporcine xenogeneic T-cell response: evidence for allelic specificity of mixed leukocyte reaction and for both direct and indirect pathways of recognition. J. Immunol. (1995) 155:5249–5256
  • YAMADA K, SEEBACH JD, DERSIMONIAN H, SACHS DH. Human antipig T-cell mediated cytotoxicity. Xenotrans-plantation (1996) 3:179–187
  • CHAVEZ G, COZZI E, THIRU S et al.: Pig to primate cellular xenograft rejection, a humoral independent process. Abstract presented at the 5th Congress of the International Xenotransplantation Association. Nagoya, Japan (1999).
  • LECHLER RI: Manipulating xenoreactive T-cells: Role of T-cell responses in rejection. Plenary session presented at the 5th Congress of the International Xenotransplantation Association. Nagoya, Japan (1999).
  • SYKES M, SACHS DH: Xenogeneic tolerance through hematopoietic cell and thymic transplantation. In: Xenotransplantation - The Transplantation Of Organs And Tissues Between Species, (Second Edition). Cooper DKC, Kemp E, Platt JL, White DJG (Eds.), Springer, Heidelberg, Germany (1997):496–518.
  • ••Excellent review of work attempting to induce tolerance toxenografts.
  • SACHS DH, SYKES M, GREENSTEIN JL, COSIMI AB: Tolerance and xenograft survival. Nature Med. (1995) 1:969.
  • BARTHOLOMEW AM, POWELSON J, SACHS DH et al.:Tolerance in a concordant nonhuman primate model. Transplantation (1999) 68:1709.
  • OHDAN H, YANG YG, SHIMIZU A et al.: Mixed chimerism induced without lethal conditioning prevents T-cell- and antiGal a 1,3Gal-mediated graft rejection. J. Clin. Invest. (1999) 104:281–290.
  • BRACY JL, SACHS DH, IACOMINI J: Inhibition of xenore-active natural antibody production by retroviral gene therapy. Science (1998) '281:1845–1847.
  • •First description of gene therapy to induce B-cell tolerance of relevance to xenotransplantation.
  • IERINO FL, GOJO S, BANERJEE PT eta/.: Transfer of swine major histocompatibility complex class II genes into autologous bone marrow cells of baboons for the induction of tolerance across xenogeneic barriers. Transplantation (1999) 67:1119–1128.
  • YAMADA K, SHIMIZU A, IERINO FL et al.: Thymic transplantation in miniature swine: 1. Development and function of the ihymokidney'. Transplantation (1999) '68:1684–1692.
  • KAWAI T, COSIMI B, COLVIN R et al. Mixed allogeneicchimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation (1995) 59:256–262.
  • SPITZER TR, DELMONICO F, TOLKOFF-RUBIN N et al.: Combined histocompatible leukocyte antigen-matched donor bone marrow and renal transplanta-tion for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplanta-tion (1999) 68:480–484.
  • •Report of patient in whom immunologic tolerance was induced following concomitant bone marrow and kidney transplantation from the same donor.
  • NASH K, CHANG Q, WATTS A et al.: Peripheral blood progenitor cell mobilization and leukapheresis in pigs. Lab. Anim. Sci. (1999) 49:645–649.
  • VAN ROOIJEN N, SANDERS A. Liposome mediated depletion of macrophages: mechanism of action, preparation ofliposomes and applications./ Immunol. Methods (1994) 174: 83–93
  • BUHLER L, GOEPFERT M, KITAMURA H et al Porcine hematopoietic cell xenotransplantation in nonhuman primates is complicated by a thrombotic microangio-pathy. (Submitted)
  • ALWAYN IPJ, APPEL JZ III, GOEPFERT C, BUHLER L, COOPER DKC, ROBSON SC: Inhibition of platelet aggregation in baboons: therapeutic implications for xenotransplantation. (Submitted).
  • COOPER DKC, KOREN E, ORIOL R: Genetically engineered pigs [letter]. Lancet (1993) 342:682–683.
  • OSMAN N, MCKENZIE IF, OSTENRIED K et al.: Combinedtransgenic expression of a-galactosidase and a 1,2-fucosyltransferase leads to optimal reduction in the major xenoepitope Gala (1,3) Gal. Proc. Natl. Acad. Sci. USA (1997) 94:14677–14682.
  • SHINKEL TA, CHEN CG, SALVARIS E et al.: Changes in cellsurface glycosylation in a 1,3-galactosyltransferase knockout and a 1,2-fucosyltransferase transgenic mice. Transplantation (1997) 64:197–204.
  • SANDRIN MS, FODOR WL, MOUHTOURIS E et al.: Enzymatic remodelling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nature Med. (1995) 1:1261–1267.
  • CHEN D, RIESBECK K, KEMBALL-COOK G et al.: Inhibi-tion of tissue factor-dependent and-independent coagulation by cell surface expression of novel antico-agulant fusion proteins. Transplantation (1999) 67:467–474
  • ALEXANDRE GPJ, SQUIFFLET JP, DE BRUYERE M et al.:Present experience in a series of 26 abo-incompatible living donor renal allografts. Transplant. Proc. (1987) 19:4538.
  • BACH FH, PLATT J, COOPER DKC: Accommodation - therole of natural antibody and complement in discor-dant xenograft rejection. In: Xenotranp/antation. Cooper DKC, Kemp E, Reemtsma K, White DJG (Eds.), Springer, Heidelberg, Germany (1991):81–99.
  • BACH FH, TURMAN MA, VERCELLOTTI GM, PLATT JL,DALMASSO AP: Accommodation: a working paradigm for progressing toward clinical discordant xenografting. Transplant. Proc. (1991) 23:205–207.
  • TANEMURA M, MARUYAMA S, GALILI U: Differential expressionofa-GALepitopes(Gala1-3Galf31-4GkNAc-R) on pig and mouse organs. Transplantation (2000) 69:187–190.
  • TANEMURA M, YIN D, CHONG AS, GALILI U: Differential immune responses to a-gal epitopes on xenografts and allografts: implications for accommodation in xenotransplantation. J. Clin. Invest. (2000) 105:301–310.
  • •Interesting studies on factors influencing success or failure of achieving accommodation of allografts and xenografts.
  • LACHMANN PJ, HALBWACHS L: The influence of c3b inactivator (kaf) concentration on the ability of serum to support complement activation. Clin. Exp. Immunol. (1975) 21:109–114.
  • COOPER DKC: Xenoantigens and xenoantibodies. Xenotransplantation (1998) 5:6–17.

Websites

  • BUHLER L, FRIEDMAN T, IACOMINI J, COOPER DKC: Xenotransplantation - state of the art: update 1999. Front. Biosci. (1999) 4:D416-432. http://www.Bioscience.Org/1999N4/D/Buhler/ Fulltext.Htm
  • •Reviews immunologic barriers to successful xenotransplan-tation and therapeutic approaches being explored.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.